

# Penelitian IKM/Epidemiologi

Oleh : Suyatno, Ir. MKes


Contact:

E-mail: [suyatnofkmundip@gmail.com](mailto:suyatnofkmundip@gmail.com)

Blog: [suyatno.blog.undip.ac.id](http://suyatno.blog.undip.ac.id)

Hp/Telp: 08122815730 / 024-70251915

# Epidemiologic Study Designs



# **Epidemiologic Study Designs**

## ***Descriptive studies***

**Examine patterns of disease**


## ***Analytical studies***

**Studies of suspected causes of diseases**


## ***Experimental studies***

**Compare treatment modalities**

# Epidemiologic Study Designs



# Hierarchy of Epidemiologic Study Design




# Observational Studies

(no control over the circumstances)

- Descriptive: Most basic demographic studies
- Analytical: Comparative studies testing an hypothesis
  - \* **cross-sectional**  
(a snapshot; no idea on cause-and-effect relationship)
  - \* **cohort**  
(prospective; cause-and-effect relationship can be inferred)
  - \* **case-control**  
(retrospective; cause-and-effect relationship can be inferred)

# Epidemiologic Study Designs



## Analytical Studies

(comparative studies testing an hypothesis)

\* **cohort** (prospective)

*Begins with an exposure (smokers and non-smokers)*

\* **case-control** (retrospective - trohoc)

*Begins with outcome (cancer cases and healthy controls)*



# Cohort Studies



## **Advantages of Cohort Studies**

- **Can establish population-based incidence**
- **Accurate relative risk (risk ratio) estimation**
- **Can examine rare exposures (asbestos > lung cancer)**
- **Temporal relationship can be inferred (prospective design)**
- **Time-to-event analysis is possible**
- **Can be used where randomization is not possible**
- **Magnitude of a risk factor's effect can be quantified**
- **Selection and information biases are decreased**
- **Multiple outcomes can be studied**  
**(smoking > lung cancer, COPD, larynx cancer)**

## **Disadvantages of Cohort Studies**

- Lengthy and expensive**
- May require very large samples**
- Not suitable for rare diseases**
- Not suitable for diseases with long-latency**
- Unexpected environmental changes may influence the association**
- Nonresponse, migration and loss-to-follow-up biases**
- Sampling, ascertainment and observer biases are still possible**

## Presentation of cohort data: Population at risk

Does HIV infection increase risk of developing TB  
among a population of drug users?

	Population (follow up 2 years)	Cases
HIV +	215	8
HIV -	289	1

Source: Selwyn et al., New York, 1989

## Does HIV infection increase risk of developing TB among drug users?

Exposure	Population (f/u 2 years)	Cases	Incidence (%)	Relative Risk
HIV +	215	8	3.7	11
HIV -	298	1	0.3	

## Presentation of cohort data: Person-years at risk

Tobacco smoking and lung cancer, England & Wales, 1951

	Person-years	Cases
Smoke	102,600	133
Do not smoke	42,800	3

Source: Doll & Hill

EPIET ([www](#))

## Presentation of data: Various exposure levels

Daily number of cigarettes smoked	Person-years at risk	Lung cancer cases
> 25	25,100	57
15 - 24	38,900	54
1 - 14	38,600	22
none	42,800	3

## Cohort study: Tobacco smoking and lung cancer, England & Wales, 1951



Cigarettes smoked/d	Person-years at risk	Cases	Rate per 1000 p-y	Rate ratio
> 25	25,100	57	2.27	32.4
15 - 24	38,900	54	1.39	19.8
1 - 14	38,600	22	0.57	8.1
none	42,800	3	0.07	Ref.

Source: Doll & Hill


EPIET ([www](#))



# Prospective cohort study



## Retrospective cohort studies



# Cohort Studies




Figure 2: **Schematic diagram of concurrent, retrospective, and ambidirectional cohort studies**

# Cohort Studies

## Panel 2: Features to look for in a cohort study

### How much selection bias was present?

- 1 Were only people at risk of the outcome included?
- 1 Was the exposure clear, specific, and measurable?
- 1 Were the exposed and unexposed groups similar in all important respects except for the exposure?

### What steps were taken to minimise information bias?

- 1 Was the outcome clear, specific, and measurable?
- 1 Was the outcome identified in the same way for both groups?
- 1 Was determination of outcome made by an observer blinded as to treatment?


### How complete was the follow-up of both groups?

- 1 What efforts were made to limit loss to follow-up?
- 1 Was loss to follow-up similar in both groups?


### Were potential confounding factors sought and controlled for in the analysis?

- 1 Did the investigators anticipate and gather information on potential confounding factors?
- 1 What method(s) were used to assess and control for confounding?

# Case-Control Studies



# Case-Control Studies



Schulz & Grimes, 2002 ([www](#)) ([PDF](#))

## **Advantages of Case-Control Studies**


- Cheap, easy and quick studies**
- Multiple exposures can be examined**
- Rare diseases and diseases with long latency can be studied**
- Suitable when randomization is unethical (alcohol and pregnancy outcome)**

## **Disadvantages of Case-Control Studies**

- Case and control selection troublesome**
- Subject to bias (selection, recall, misclassification)**
- Direct incidence estimation is not possible**
- Temporal relationship is not clear**
- Multiple outcomes cannot be studied**
- If the incidence of exposure is high, it is difficult to show the difference between cases and controls**
- Not easy to estimate attributable fraction**
- Reverse causation is a problem in interpretation - especially in molecular epidemiology studies**



# Epidemiologic Study Designs



# **Sources of Error in Epidemiologic Studies**

**Random error**

***Large sample size, replication***

**Bias**

***Be careful***

**Confounding**

**Effect Modification**

**Reverse Causation**

## Confounding can be controlled by:

- **Randomization**: assures equal distribution of confounders between study and control groups
- **Restriction**: subjects are restricted by the levels of a known confounder
- **Matching**: potential confounding factors are kept equal between the study groups
- **Stratification** for various levels of potential confounders
- **Multivariable analysis** (does not control for *effect modification*)

**Effect modification can be assessed by:**

- **Stratification** for various levels of potential confounders
- **Multivariable analysis** (by assessing interaction)

**Reverse causation can be assessed by:**

- **Mendelian Randomization**